Related Experiment Video

Updated: Nov 7, 2025

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

10.8K

E3 Ubiquitin Ligase in Anticancer Drugdsla Resistance: Recent Advances and Future Potential

Yuanqi Liu1,2, Chaojun Duan1,2,3, Chunfang Zhang1,2,4

  • 1Department of Thoracic Surgery, Xiangya Hospital, Central South University, Changsha, China.

Frontiers in Pharmacology
|May 3, 2021
PubMed

Insights

E3 ubiquitin ligases (E3s) are crucial in cancer drug resistance. Targeting these proteins offers new therapeutic strategies to overcome chemoresistance and improve patient outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Drug resistance is a major challenge in advanced cancer therapy, leading to tumor recurrence.
  • The precise mechanisms of chemoresistance remain incompletely understood.
  • E3 ubiquitin ligases (E3s) are key regulators of protein degradation and are implicated in various cellular processes.

Purpose of the Study:

  • To summarize the role of E3 ubiquitin ligases in cancer drug resistance.
  • To explore E3s as potential therapeutic targets for overcoming chemoresistance.
  • To review strategies for targeting E3s to combat drug resistance.

Main Methods:

  • Literature review focusing on E3 ubiquitin ligases and their involvement in cancer drug resistance.
  • Analysis of known E3s (e.g., MDM2, FBXW7, SKP2) and their relation to drug resistance.
  • Examination of therapeutic strategies targeting E3s.

Main Results:

  • E3s play a critical role in substrate recognition and protein ubiquitination, influencing diverse cellular functions.
  • Specific E3s, including MDM2, FBXW7, and SKP2, are linked to the development of drug resistance in cancer.
  • Targeting E3s through various strategies shows promise for overcoming chemoresistance.

Conclusions:

  • E3 ubiquitin ligases represent a promising class of targets for developing novel therapies against cancer drug resistance.
  • Understanding the mechanisms by which E3s contribute to chemoresistance can guide the development of effective treatment strategies.
  • Targeting E3s offers a potential avenue to improve therapeutic effects for cancer patients facing drug resistance.
Keywords:
E3 ubiquitin ligasecancercancer treatmentdrugdrugresistance

More Related Videos

Evaluation of Substrate Ubiquitylation by E3 Ubiquitin-ligase in Mammalian Cell Lysates09:47

Evaluation of Substrate Ubiquitylation by E3 Ubiquitin-ligase in Mammalian Cell Lysates

Published on: May 10, 2022

2.8K
In Vitro Analysis of E3 Ubiquitin Ligase Function06:06

In Vitro Analysis of E3 Ubiquitin Ligase Function

Published on: May 14, 2021

5.6K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.3K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.0K